Arcellx Signs a Development Evaluation and License Agreement with Pfenex for Advancing SparX Proteins

 Arcellx Signs a Development Evaluation and License Agreement with Pfenex for Advancing SparX Proteins

Arcellx Signs a Development Evaluation and License Agreement with Pfenex for Advancing SparX Proteins

Shots:

  • Pfenex to receive R&D funding along with $2.6M up to $18M as development, regulatory & commercial milestones and royalties on WW sales of products. Arcellx to get access to Pfenex expression technology platform to advance sparX proteins, activating, silencing & reprograming antigen- receptor complex T-cell based therapies
  • Arcellx’s first sparX protein has completed its process development program leading to the initiation of the second sparX program, both focusing on hematologic malignancies
  • The Pfenex expression technology platform is protein expression technology based on Pseudomonas fluorescens used to develop therapeutically equivalent vaccines, biologics and biosimilars which includes CRM197, PF708, PF743 & PF745

Click here to­ read full press release/ article | Ref: Globe Newswire | Image: Pfenex

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post